CellFE® today announced the launch of its highly anticipated CellFE T-Rest™, a first-in-class cell manufacturing transfection media product designed specifically for resting T cell workflows, along with an app note.
In the rapidly evolving field of cellular engineering, achieving complex gene edits with high efficiency and minimal workflow disruption remains a significant challenge.
CellFE Appoints Mike Rice to Board of Directors
CellFE announced today an upcoming presentation by CEO Alla Zamarayeva, PhD, at the International Society of Gene & Cell Therapy (ISCT) Annual Meeting, taking place May 29-June 1, 2024 in Vancouver, BC.
CellFE announced today an upcoming presentation by CSO Todd Sulchek, PhD, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 7-11, 2024 in Baltimore, MD.
CellFE announced the completion of a $22 million Series A financing led by M Ventures, with participation from Great Point Ventures, Riverine Ventures and its existing investors.
Exclusive: The California-based startup CellFE has raised a $22 million Series A to advance a new approach to making cell therapies with microfluidics.
The BIO International Convention (BIO) returns to in person meetings in San Diego, CA June 13-16 and CellFE will be there to present the…
CEO and Co-Founder Alla Zamarayeva PhD presented recently at the Startup Showcase at the ASGCT 25th Annual Conference.
Alla Zamarayeva, Co-Founder and CEO, has joined 10 women-led companies to participate in Springboard Enterprise’s 2022 Life Sciences Innovation Bootcamp.
CellFE, a microfluidics-based biotech startup based out of Alameda, CA, has recently had an article published in Scientific Reports.
CellFE will be presenting two posters at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting next week occurring from May 11-14.
